Contemporary meta-analysis data suggests GLP1-RA reduces the relative risk of cardiovascular disease (MACE) by 14% (HR 0.86 [95%CI 0.80-0.93]), and heart failure hospitalization by 11% (HR 0.89 [95%CI 0.82, 0.98]) compared to placebo3. The gene discussed is GLP1R; the disease is cardiovascular disorder.